



Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

Item 8.01 Other Events

On November 15, 2017, Ultragenyx Pharmaceutical Inc. (the “Company”) issued a press release (the “Release”) announcing that the U.S. Food and Drug Administration has approved MEPSEVII™ (vestronidase alfa) for the treatment of children and adults with Mucopolysaccharidosis VII (MPS VII, Sly syndrome).

A copy of the Release is filed herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description

99.1 Press Release of Ultragenyx Pharmaceutical Inc., dated November 15, 2017

\*\*\*

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 15, 2017

Ultragenyx Pharmaceutical Inc.

By: /s/ Shalini Sharp

Name: Shalini Sharp

Title: Executive Vice President, Chief Financial

Officer